2025年1月30日 · CD5 is a pan-T cell marker belonging to the scavenger receptor cysteine rich (SRCR) superfamily of receptors (Eur J Immunol 2016;46:1490) Used for diagnosis of lymphomas and thymic carcinoma Helps differentiate chronic lymphocytic leukemia (CLL) and mantle cell lymphoma from other types of low grade B cell non-Hodgkin lymphomas

2023年5月18日 · Several other anti-CD38 antibodies, including bispecific anti-CD3 / CD38 antibodies, are in development or have recently been approved for treatment in multiple myeloma (e.g., isatuximab, approved March 2020) (Front Immunol 2018;9:2722, Front …

Hodgkin lymphoma: ALK1 CD3 CD15 CD20 CD30 CD45 (LCA) EBER1 / 2 / LMP PAX5 Leukemia: CD3 CD34 CD68 c-kit / CD117 E-cadherin MPO NPM1 PAX5 TdT Non-Hodgkin lymphoma & myeloma: BCL6 CD3 CD5 CD10 CD15 CD20 CD23 CD30 CXCR3 kappa & lambda light chains Ki67

2024年3月19日 · Pan T cell marker Diagnosis of myeloid (granulocytic) sarcoma (J Clin Pathol 2005;58:211) Classify subtypes of T cell lymphomas and low grade B cell lymphomas Differentiate pulmonary MALT lymphoma (CD20+ CD43+) from lymphoid hyperplasia (CD43 negative, Am J Surg Pathol 2002;26:76)

Javascript is required. Please enable javascript before you are allowed to see this page.

Immunohistochemical stains are performed. The neoplastic cells are positive for CD2, CD5, CD8 and CD30 and are negative for CD3, CD4, CD7, CD10, CD56, TCR alpha beta and TCR gamma delta. Epstein-Barr virus encoding region (EBER) in situ hybridization is negative.

2021年8月23日 · Comment: CD20 highlights large atypical B cells within small B cell rich nodules. CD3 is positive in background small T cells with occasional CD3 positive T cell rosettes around the large atypical B cells. A PD-1 stain shows T cell rosettes encircling the large atypical B cells in the nodular areas.

2023年2月9日 · Marker of NK cells and NK lymphomas Detects residual myeloma and residual acute myeloid leukemia in bone marrow ( Am J Clin Pathol 2009;132:60 , Am J Clin Pathol 2008;129:934 ) Differentiates plasma cells in myeloma (CD56+) from reactive plasmacytosis or monoclonal gammopathy of undetermined significance (MGUS) (CD56-) ( Am J Pathol …

2021年9月20日 · Widely used B cell marker (also CD19, CD79a, PAX5) Retained on mature B cells until plasma cell differentiation Anti-CD20 therapy (e.g., rituximab) is available for treatment of non-Hodgkin B cell lymphoma and autoimmune diseases

2024年6月13日 · Plasma cells. CD138 is a useful marker of plasma cells and can help support a diagnosis of multiple myeloma. Answers B, C and D are incorrect because CD138 is not a useful marker in identifying T or B cells. While B cells may express CD138 during earlier stages of development, they lose expression of this marker at maturity.